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Introduction
Anti-neutrophil cytoplasmic antibody (ANCA)-asso  cia-
ted vasculitis (AAV) is a life-threatening form of auto-
immune small-vessel vasculitis. AAV comprises three 
similar disease entities: Churg-Strauss syndrome (CSS), 
microscopic polyangiitis (MPA), and Wegener’s granulo-
matosis (WG). Th   ese three entities have the presence of 
ANCA in common. CSS and MPA patients usually have 
ANCA directed to myeloperoxidase (MPO), whereas in 
WG, ANCA is in most cases directed to proteinase-3 
(PR3) [1]. All three diseases are associated with systemic 
vasculitis and pauci-immune crescentic, necrotizing 
glomerulonephritis [2]. In addition, in many patients 
with WG or CSS, necrotizing granulomatous inﬂ  amma-
tion of the airways is observed. However, the histological 
ﬁ  ndings vary slightly between the disease entities; tissue 
inﬁ  ltration with eosinophils is observed mainly in CSS, 
whereas neutrophils are found in WG. Often, T cells are 
present within these granulomas [3]. In accordance with 
these ﬁ  ndings, serum levels of markers of T-cell activity 
such as soluble interleukin-2-receptor (sIL-2r), neopterin, 
and soluble CD30 are elevated in AAV and associated 
with disease activity [4-6]. Increased numbers of T cells 
reactive to the sense or complementary Wegener auto-
antigen PR3 are detectable in some but not all WG 
patients [7,8]. In addition, ANCAs have an IgG isotype, 
suggesting that a T cell-mediated class switch has taken 
place. Importantly, Ruth and colleagues [9] demonstrated 
in an animal model of AAV that T-helper-cell depletion 
ameliorates the course of the disease. Speciﬁ   c T cell-
targeted therapy is occasionally used in refractory cases 
with AAV and this has been demonstrated to have a 
beneﬁ  cial  eﬀ   ect on the course of the disease [10]. 
Altogether, these ﬁ  ndings suggest that T cells are involved 
in the pathogenesis of AAV. Th   e newest ﬁ  ndings obtained 
during the last two decades will be discussed in this 
review. Hallmarks of T-cell pathology such as deﬁ  cient 
regulation of T cells, memory T-cell expansion, persistent 
T-cell activation as well as T-cell polarization are dealt 
with; subsequently, T cell-driven granuloma and tertiary 
lymphoid organ (TLO) formation is discussed.
Regulatory versus eff  ector memory T cells
Two major subsets of T cells are thought to dominate the 
adaptive T-cell immune response: regulatory T cells 
(Tregs) and CD4+ eﬀ  ector T cells (Teﬀ  s). Tregs limit and 
regulate the immune response, whereas Teﬀ  s  are 
‘executors’ controlled by Tregs. If this control is not 
regulated properly, excessive immune responses and loss 
of self-tolerance will follow (Figure 1). According to this 
concept, Treg and Teﬀ   subsets are the focus of research 
Abstract
Anti-neutrophil cytoplasmic antibody (ANCA)-
associated vasculitis (AAV) is a life-threatening 
autoimmune disease characterized by an antibody-
mediated glomerulonephritis and necrotizing 
vasculitis. Apart from antibodies, T cells are also 
involved in disease pathogenesis. This review stresses 
the hallmarks of T cell-mediated pathology in AAV and 
highlights the characteristics of lesional and circulating 
T cells in the immune response in AAV. Circulating 
eff  ector T-cell populations are expanded and are in a 
persistent state of activation. Circulating regulatory 
T-cell subsets are less well characterized but seem to 
be impaired in function. Lesional eff  ector T cells are 
present in granulomas, vasculitic lesions, and nephritis. 
Lesional T cells usually show pro-infl  ammatory 
properties and promote granuloma formation. Apart 
from T cells, dendritic cells are abundantly present at 
the sites of infl  ammation and locally orchestrate the 
immune response. Targeting the above-mentioned 
T cell-mediated disease mechanisms will potentially 
provide powerful therapeutic tools for AAV.
© 2010 BioMed Central Ltd
T cells in ANCA-associated vasculitis: what can we 
learn from lesional versus circulating T cells?
Benjamin Wilde1,2, Marielle Thewissen1, Jan Damoiseaux1, Pieter van Paassen1, Oliver Witzke2 
and Jan Willem Cohen Tervaert*1
REVIEW
*Correspondence: secretariaat-immuno@immuno.unimaas.nl
1Department of Internal Medicine, Division of Clinical and Experimental 
Immunology, University Hospital Maastricht, Universiteitssingel 50, PO Box 616, 
6200 MD Maastricht The Netherlands
Full list of author information is available at the end of the article
Wilde et al. Arthritis Research & Therapy 2010, 12:204 
http://arthritis-research.com/content/12/1/204
© 2010 BioMed Central Ltdin AAV. Indeed, numerous reports have conﬁ  rmed an 
expanded circulating CD4+CD25+ T-cell population in 
AAV [4,11-13]. Th   is T-cell subset usually contains activated 
Teﬀ s as well as Tregs [14] (Table 1).
Abdulahad and colleagues [13,15] diﬀ  erentiated between 
CD25low (activated Teﬀ  ) and CD25high (Treg) CD4+ T cells 
and found an increase of both populations in patients 
with WG (Table 1). Moreover, an increase of both FoxP3+ 
Tregs and FoxP3− eﬀ   ector memory T cells (Tems) in 
patients with remission was described [13], whereas in a 
previous study by Marinaki and colleagues [11], no 
increase of circulating FoxP3+ Tregs was observed. 
Abdulahad and colleagues [15] demonstrated a functional 
impairment of CD25high Tregs in WG. Th   ese Tregs failed 
to inhibit proliferation or cytokine production of 
responder T cells. However, selection criteria of Tregs 
and their inﬂ   uence on the test system assessing Treg 
functionality have been recently studied [16]. When 
Tregs were sorted by CD25 and CD127, Tregs showing 
CD25high expression ﬁ   rst appeared to be impaired in 
function; excluding CD127+ CD25high T cells restored 
functionality [16]. Th  us, the defect of CD25high  Tregs 
observed in WG might be biased by Treg selection 
criteria. In addition, there is an ongoing dispute on the 
speciﬁ  city of the anti-FoxP3 clone PCH101 commonly 
used for determining Treg frequency as well as purity 
[15,17,18]. Th   erefore, additional studies are necessary to 
conﬁ  rm whether there is a defect of Treg function in 
WG. Furthermore, functional and descriptive Treg 
studies using new markers such as CD127, CD39, and 
CD73 have not yet been published and are necessary 
[19,20].
Factors inﬂ   uencing Treg homeostasis and function 
might be involved in the pathogenesis of AAV. For 
instance, leptin has recently emerged as a controller of 
immunity and especially as a controller of Tregs. Leptin 
itself is considered to have pro-inﬂ  ammatory  eﬀ  ects, 
whereas neutralization of leptin leads to Treg expansion 
in vitro [21]. Surprisingly, Kümpers and colleagues [22] 
recently found decreased levels of leptin in patients with 
WG and MPA during active disease. Leptin levels 
normalized again when entering remission. Low levels of 
leptin observed during active disease might lead to Treg 
expansion, restoration of tolerance, and attenuation of 
the inﬂ  ammatory response [23].
Apart from an obvious CD25+ T-cell expansion both in 
patients with active disease and in those in remission [4], 
memory T cells are expanded in AAV [11] (Table 1). 
Marinaki and colleagues [24] described low numbers of 
naïve T cells in AAV as compared with healthy controls 
(HCs). In line with this study, Abdulahad and colleagues 
[15] reported an increase of circulating Tems in WG 
patients in remission. In active WG, the numbers of 
circulating Tems dropped and could be detected in urine, 
suggesting that Tems migrate from the circulation to 
inﬂ  am  matory sites during active states of the disease [25].
Recently, we conﬁ  rmed the ﬁ  ndings by Abdulahad and 
colleagues [12,13] and found an expan  sion of speciﬁ  c 
circulating CD25+ Tem subpopulations in WG. Th  ese 
CD25+ Tems were CD134+ and GITR+ and did not show a 
regulatory phenotype (Table 1). CD134+ T cells were also 
found in inﬂ   ammatory lesions. Interestingly, the 
expansion of speciﬁ  c CD134+ and GITR+ Tem subsets 
was closely associated with disease activity [12]. However, 
these ﬁ  ndings are in contrast to the study of Abdulahad 
and colleagues [13] on the overall Tem population that 
decreases during active disease. We postulate that speciﬁ  c 
Tem subsets increase during active disease despite a total 
decrease of Tems. Indeed, Tems are a heterogenous T-cell 
population and might show varying proliferation, survival, 
and migratory capacities [26].
Of special interest is the Treg/Tem balance in vivo. In 
the ﬁ  eld of transplant immunology, ratios between Tregs 
and Tems are regarded as important for immune 
tolerance. Recently, Kreijveld and colleagues [27] assessed 
the value of these ratios before and after kidney 
transplantation and found that the ratio was predictive of 
rejection. It was demonstrated that a rejection was 
preceded by a shift from Tregs to Tems. One could 
speculate that these ratios are also skewed toward Tems 
in WG, especially in case of a relapse. However, this has 
been scarcely investigated so far. In one study, Treg/Tem 
ratios were assessed in WG and no diﬀ  erences  were 
found when compared with HCs [13]. Furthermore, an 
association with disease activity was not found. Further 
studies are needed to see whether monitoring the Treg/
Tem ratio could be an option for predicting relapses. In 
AAV, the balance of Tregs and Tems might be altered, 
leading to less strict control of the immune response 
(Figure 1). Th   is might promote loss of self-tolerance and 
autoimmunity (Figure 1).
Aberrant T-cell activation and senescence in AAV
Aberrant T-cell costimulation and T-cell senescence 
might have a role in the expansion of Tems in AAV and 
this might facilitate the breakdown of self-tolerance. 
Indeed, T cells in AAV show an altered expression 
pattern of costimulatory molecules. Th  is is well studied 
with regard to the CD28/CD80 pathway [28-30]. Normally, 
CD28 is present on T cells whereas CD80/86 is found on 
antigen-presenting cells (APCs). Antigen presen  tation of 
APCs to T cells requires additional signaling via the 
CD28/CD80 pathway, resulting in T-cell activation.
Strikingly, CD28 is downregulated on circulating and 
lesional CD4+ T-helper cells in AAV [28,29]. Th  ese 
CD28null T cells are described as a major source of pro-
inﬂ  ammatory cytokines such as interferon-gamma (IFNγ) 
and tumor necrosis factor-alpha (TNFα) [31]. Moreover, 
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Page 2 of 9Figure 1. Pathways contributing to disease mechanisms in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). 
The ‘classic neutrophil pathway’ has been studied and confi  rmed by several groups. This pathway causes necrotizing vasculitis [87]. We propose an 
additional ‘T-cell pathway’ that mainly causes granulomatous infl  ammation and promotes necrotizing vasculitis. Infections are the starting point 
of both pathways; infections trigger priming of neutrophils, upregulation of adhesion molecules on endothelial cells, and expansion of circulating 
eff  ector T cells (Teff  s). Primed neutrophils show increased surface expression of ANCA antigens and adhesion molecules. ANCA binding activates 
the neutrophil in the following ways: 1) enhancing vessel wall adherence and transmigration capacity, 2) production and release of oxygen radicals, 
and 3) degranulation and release of enzymes, including myeloperoxidase (MPO) and proteinase-3 (PR3). Transient immune complexes are formed 
locally by binding of ANCA to PR3/MPO sticking to endothelial cells. Subsequently, complement is activated. This all adds to the development of 
necrotizing vasculitis. The expanded eff  ector memory T cells (Tems) are not suffi   ciently regulated by regulatory T cells (Tregs), leading to dysbalance 
in the homeostasis of Tregs and Tems and resulting in further release of pro-infl  ammatory cytokines promoting neutrophil priming; moreover, 
ANCA production is enhanced by further T cell/B cell interaction. Expanded circulating Tems migrate into target organs such as the lungs or the 
kidney. Within tissues, Tems drive formation of granuloma, which is considered an ‘executioner’ of tissue destruction. Granulomas are composed 
of numerous cell types such as T cells, B cells, giant cells, and dendritic cells. Moreover, ANCA production occurs in granulomas. Possibly, tertiary 
lymphoid organs (TLOs) are ‘local controllers’ of tissue infl  ammation since induction of Tregs is thought to take place in TLOs. ICX, immune complex. 
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perforin as well as NKG2D [30,32]. Th   ese latter features 
are usually conﬁ  ned to cytolytic natural killer-like T cells 
(Table  1). In AAV, CD28null T cells have shortened 
telomeres and they express CD57, which is indicative of 
replicative senescence [31,33]. CD28null T cells are supposed 
to have a role in several other autoimmune diseases and 
are less responsive to immunoregulation [34]. Although 
there is a positive correlation with disease severity and 
the presence of CD28null T-helper cells in AAV patients, a 
direct pathogenic role has not been proven yet but seems 
to be likely. Th   erefore, the presence of CD28null T-helper 
cells might also be considered to be secondary to latent 
viral herpes infections such as cytomegalovirus (CMV) 
since these T cells have antigen speciﬁ  city for CMV but 
not to autoantigens [34,35]. Th  e  deﬁ  nitive role of CD28null 
T-helper cells in AAV needs to be further investigated.
Th  e costimulatory molecules CD80 and CD86 are 
upregulated on T cells in WG after in vitro stimulation 
with mitogens and polyclonal stimuli [29]. Th  e  functional 
properties of CD80+ T-helper cells have not been 
assessed in AAV so far. However, it is known that CD80 
expression on T-helper cells in general is accompanied by 
major histocompatibility complex class II expression 
[36,37]. Th  erefore,  CD80+ T cells might be able to present 
antigen to other T cells. Th   is presentation might lead to 
activation or – as recently described in a mouse model – 
inhibition of T-cell responses [37]. Th   us, it is not known 
whether the aberrant CD80 expression observed in AAV 
favors persistent stimulation of T cells or limits the 
immune response.
An increased expression of CTLA-4 on CD4+ T cells 
has been reported in WG [30]. CTLA-4 is a negative 
costimulator that binds to CD80/CD86 on APCs and 
thereby inhibits CD28-dependent T-cell activation. 
CTLA-4 might counterbalance T-cell activation in AAV. 
Overexpression of CTLA-4 is accompanied by upregu-
lation of anti-apoptotic BCL-2 [38]. Th  us, these T cells 
seem to be protected against activation-induced cell 
death [38]. Other negative costimulators such as PD-1 
have not been assessed in AAV so far.
Genetic polymorphisms of CTLA-4 have also been 
studied in AAV [39]. Some polymorphisms of the 
negative costimulator CTLA-4 have a higher prevalence 
in AAV than in HCs [40-42]. Dinucleotide repeats within 
the gene encoding CTLA-4 were linked to AAV by 
several authors [41,42]. Elongated repeats lead to insta-
bility of mRNA and also contribute to hyper-reactivity of 
T cells [43]. Other associated polymorphisms in the 
CTLA-4 gene are known to reduce the availability and 
surface expression of this negative costimulator. Th  us, 
associated polymorphisms might limit the eﬃ   cacy  of 
CTLA-4 upregulation. Moreover, we studied polymor-
phisms of another negative costimulator, the PDCD 
(PD-1) gene [42]. Genetic variants of PD-1 were not 
directly linked to WG or AAV, but speciﬁ  c combinations 
of CTLA-4 and PD-1 polymorphisms were less prevalent 
in AAV [42].
Besides changes in the expression of costimulatory 
molecules, other markers of T-cell activation are either 
upregulated or downregulated in AAV patients. For 
instance, HLA-DR expression of CD4+ T-helper-cells is 
Table 1. T-cell subsets involved in disease pathogenesis of AAV.
T-cell subset  Characteristics  Findings in AAV  Reference
CD4+CD25+   Consists of two functionally diff  erent subsets:   CD4+CD25+ T cells are expanded.   Marinaki et al. [11] 
 activated  eff  ector T cells (intermediate CD25     Popa et al. [4]
  expression) and Tregs (high CD25 expression)
CD4+CD25highFoxP3+CD127low  Naturally occurring Tregs, potent suppressors, and   Defect in function reported, but diff  erent  Abdulahad et al. [15]
  proliferation and cytokine production of eff  ector   Treg defi  nition was used (CD25highFoxP3+). 
 T  cells
CD4+CD45RO+CCR7− Eff  ector memory T cells migrate to peripheral   Expanded, decrease during active state  Abdulahad et al. [13]
  tissues but not to lymphatic tissue.  of disease 
CD4+CD25+CD134+/GITR+  Specifi  c T-cell subset, mainly of eff  ector memory   Increased in AAV, association with disease  Wilde et al. [12]
  T-cell type  activity and infl  ammation 
CD28nullNKGD2+Perforin+  Senescent T cells, IFNγ, and TNFα producers;   Expanded, abundantly present in granulomas  Lamprecht et al. [28]
 cytotoxic  properties   
CD4+CD45RClow  Produces type 2 cytokines as well as IL-10 and IL-17  Increased in AAV  Ordonez et al. [59]
CD4+CCR5+IFNγ+  IFNγ cells are, by defi  nition, Th1 cells and enhance   Skewing toward Th1 in localized WG  Csernok et al. [49]
  cellular immune responses.    
CD4+CCR3+IL-4+  By defi  nition, Th2 cells promote humoral   Skewing toward Th2 in CSS and systemic WG  Kiene et al. [50] 
 immune  responses.    Balding  et al. [48]
CD4+IL-17+  By defi  nition, Th17 cells; IL-17 attracts and   Skewing toward Th17 in WG during quiescent  Abdulahad et al. [8]
  activates neutrophils.  disease and in CSS during active disease   Saito et al. [58]
AAV, anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis; CSS, Churg-Strauss syndrome; IFNγ, interferon-gamma; IL, interleukin; TNFα, tumor necrosis 
factor-alpha; Treg, regulatory T cell; WG, Wegener granulomatosis.
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poorly [4]. In addition, levels of soluble T-cell activation 
markers such as sIL-2r, sCD4, sCD8, sCD30, and 
neopterin are increased in AAV [6,44-46]. Some studies 
showed an association of these markers and disease 
activity, while others failed to demonstrate a correlation 
with disease activity [4-6,44,46,47]. Taken together, T cells 
in AAV are in a state of persistent activation, not only 
during active disease but also during remission. Th  is 
might be caused or followed by an aberrant expression of 
costimulatory molecules. Th   is aberrant expression 
pattern might favor Tem expansion and thus contribute 
to the dysbalance of Tregs and Tems (Figure 1).
The myriad of T-helper-cell polarization in AAV
In AAV, there are diﬀ   erences in Teﬀ    type 1/type 2 
polariza  tion, depending on disease type and disease stage 
[48,49]. As suggested by features of CSS such as asthma 
and eosinophilia, CSS seems to be associated with Th  2 
polarization. Kiene and colleagues [50] analyzed T-cell 
lines of CSS and WG patients. Higher levels of IL-4 and 
IL-13 were detected in CSS than in WG, whereas elevated 
levels of IFNγ were produced by T cells in both CSS and 
WG. Th   us, a stronger Th   2 polarization was seen in CSS 
[50] (Table 1).
T-cell polarization in MPA is not well studied and data 
are conﬂ   icting. Some hints point at Th  1 polarization 
where  as others indicate Th   2 polarization in MPA. It has 
been shown that, during active disease, soluble CX3CL1 
levels are elevated and that CX3CR1 expression on 
circulating T cells correlates with disease activity. 
CX3CL1 is a chemokine belonging to the fractalkine 
family and is suggested to be associated with a prefer-
ential Th  1 response [51]. In addition, levels of the Th  2-
associated marker sCD30 were not elevated in MPA 
during active disease [52]. However, the Th  1 marker 
sCD26 was found to be decreased in active MPA and 
increased during remission [52]. Th  ere are only limited 
data on lesional T cells in MPA; interestingly, these 
T cells were not capable of producing Th  1  cytokines  like 
IFNγ but instead secreted Th   2 cytokines [53].
In WG, it is claimed that localized disease is associated 
with a preferential Th   1 response whereas Th  2  responses 
are common in systemic disease. Plasma levels of sCD26 
as a marker for Th   1 response are elevated in patients with 
localized disease [52]. Lamprecht and colleagues [54,55] 
compared CCR5 (Th  1) and CCR3 (Th  2) expression on 
circulating T cells from patients with WG. In localized 
disease, there was a higher expression of CCR5 indicative 
for Th   1 response whereas the two markers were 
expressed at equal levels in systemic disease (Table 1). 
Furthermore, some studies have characterized lesional 
T  cells derived from granulomas of nasal biopsies. 
Interestingly, data from two studies suggest that the 
polarization of tissue-resident T cells depends on disease 
extent. In localized WG, T cells were mainly positive for 
CD26 and IFNγ, suggesting a preferential Th  1  response, 
whereas in systemic WG, lesional T cells show a Th  2-like 
response with little IFNγ and high IL-4 expression 
[48,56]. In contrast to these studies, however, Csernok 
and colleagues [49] detected high levels of IFNγ mRNA 
and low levels of IL-4 mRNA produced by lesional T cells 
derived from nasal biopsies of patients with systemic 
disease. In line with this study, Komocsi and colleagues 
[31] characterized lesional T cells in granulomas by 
immunohistochemistry and found them to be main 
producers of IFNγ and TNFα. It remains to be conﬁ  rmed 
whether there is a shift in T-cell polarization along with 
progression from localized to systemic disease.
Another T-helper-cell subset that was recently shown 
to be of major importance in autoimmunity is the IL-17-
producing T-cell subset (Th   17) [57]. Th   ere are some hints 
indicating that a skewed Th  17 response might also 
contribute to the disease pathogenesis of AAV [8]. It was 
recently reported that WG patients in remission bear an 
increased number of circulating Th   17 cells reactive to the 
autoantigen PR3 [8]. In addition, CSS patients with active 
disease have an increased number of circulating Th  17 
cells [58]. Moreover, AAV patients harbor an expanded 
CD45RC T-helper-cell population that is a source of 
IL-17 [59] (Table 1). IL-17 also facilitates the migration 
and activation of neutrophils by promoting the secretion 
of TNFα and IL-1β [60]. Since the inﬂ  ux of neutrophils is 
a hallmark of AAV, IL-17 might enable the migration of 
neutrophils during active vasculitis. Th   e data on 
T-helper-cell polarization are inconclusive at some points 
and the evidence on Th  17 subsets is limited, so the 
importance of T-cell polarization needs to be further 
studied in AAV patients.
Local infl  ammation in AAV: T cells, granuloma 
formation, and tissue damage
Circulating T cells migrate into tissue during the active 
phase of disease. Th   ese T cells, present in lesions within 
organs aﬀ   ected by AAV, have multiple important 
functions in driving the disease (Figure 1). In general, the 
following lesions are commonly found: granuloma 
formation with central necrosis, vasculitis of small- and 
medium-sized vessels, inﬁ   ltration with mononuclear 
cells, and necrotizing crescentic glomerulonephritis 
without deposits of immune complexes.
Granulomas, which can be detected in WG and CSS 
but not in MPA, have been demonstrated to be composed 
of T cells, B cells, giant cells, and dendritic cells (DCs) 
(Figure 1). Granulomas are observed in the upper 
airways, the lungs, and occasionally in other organs such 
as the kidneys [61]. Th   e cellular subsets participating in 
granulomatous inﬂ  ammation are best characterized by 
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In these granulomatous lesions, a dense T-cell inﬁ  ltrate is 
usually found. CD4+ T cells slightly outnumber CD8+ T 
cells [56]. Th   e T cells express CD45RO and show a CD28− 
phenotype. Further analysis reveals CD28null T cells as 
major producers of IFNγ and TNFα [31]. Th  ese 
phenotypic features imply that most of the T cells within 
the inﬂ  amed tissue belong to the senescent memory T-
cell population [62]. As mentioned above, the numbers of 
circulating Tems are found to be decreased in patients 
with active disease. Given the data from biopsy studies, it 
is possible that memory T cells migrate from the 
circulation to the tissue to act as eﬀ  ector cells [13].
Presumably, these migrating Teﬀ  s act in diﬀ  erent ways. 
It is well accepted that granuloma formation is driven by 
Teﬀ s [63]. For instance, granuloma formation is severely 
impaired after CD4+ T-cell depletion in mice models of 
tuberculosis. Similarly, low CD4+ T-cell counts in HIV 
result in an increased susceptibility to tuberculosis and 
poorly organized granulomas. In addition, the impor-
tance of T cell-derived cytokines such as TNFα and INFγ 
to granuloma formation has been demonstrated [63]. 
Interestingly, Csernok and colleagues [53] reported that 
lesional T cells in MPA lack production of IFNγ, which is 
thought to be essential for granuloma formation. Th  is 
ﬁ   nding might provide an explanation of why granulo-
matous inﬂ  ammation is absent in MPA. Th  us, the T-cell 
inﬁ  ltrate in AAV seems to be indispensable for initiation 
and sustaining of granulomatous inﬂ  ammation, contri  but-
ing in a direct way to the tissue damage observed in AAV.
Cytotoxic CD8+ T cells are also present in inﬂ  amed 
tissue in AAV. Th  ese cells are capable of inducing 
apoptosis and may be cytotoxic for endothelial cells. 
Furthermore, it has been shown that CD4+CD28null 
T cells have cytolytic properties [34]. As these T cells are 
abundantly present in inﬂ  ammatory lesions in AAV, a 
destructive role for these cells has to be considered as 
well [28]. In line with these ﬁ   ndings, a recent report 
demonstrated that CD4+ Tems can damage endothelial 
cells and it was found that this process was independent 
of the CD28 costimulatory pathway, supporting a role for 
CD4+CD28null Tems in mediating tissue damage [64]. 
Next to CD4+CD28null T cells, CD4+CD134+ Teﬀ s also are 
present in vasculitic and renal lesions [12]. It has been 
reported that the ligand for CD134 is expressed on 
endothelial cells [65]. Ligation of CD134 promotes T cells 
to adhere to endothelial cells and this interaction subse-
quently stimulates T cells to produce pro-inﬂ  ammatory 
cytokines [66]. Indeed, pro-inﬂ  ammatory cytokines are 
expressed in kidneys and other tissues aﬀ  ected by AAV 
[31,67]. Although an exact mechanism of tissue damage 
has not yet been demonstrated for CD4+CD134+ T cells, 
it can be hypothesized that pro-inﬂ  ammatory cytokines 
such as IFNγ cause direct damage to endothelial cells 
[68]. However, pro-inﬂ   ammatory cytokines may also 
mediate damage by promoting neutrophil-endothelial 
adhesion and neutrophil activation, ﬁ   nally leading to 
tissue damage [69]. Th  us, lesional T cells bear the 
potential to destroy tissue integrity by driving granuloma 
formation, by cytokine production, or by direct eﬀ  ects on 
target cells (Figure 1).
Local infl  ammation in AAV: tertiary lymphoid 
organ formation
As discussed above, T cells act as eﬀ  ectors in inﬂ  amed 
organs. Th  e questions arises of whether there is any 
‘tissue-resident’ surveillance on this inﬂ  ammatory 
process. At present, it is unknown whether local 
activation or control of the immune response within the 
aﬀ   ected tissue itself occurs in AAV. Local control of 
immune responses is linked to the development of TLOs 
and this is also known as lymphoid neogenesis [70]. Th  is 
has been described for several chronic inﬂ  ammatory 
conditions (for example, rejection in the context of organ 
transplantation and inﬂ  ammation in several autoimmune 
diseases) [70]. TLOs resemble the structure of secondary 
lymphoid organs and consist of B-cell follicles with a 
surrounding mantle zone with T cells and DCs. Within 
these TLOs, T-cell activation by APCs such as DCs and 
B-cell stimulation take place. It is likely that local, tissue-
speciﬁ   c (auto)antigens are presented there. Whereas 
secondary lymphoid organs have organized lymph ﬂ  ow 
and APC traﬃ   cking, TLOs lack these features, resulting 
in an unrestricted access of antigens, APCs, and 
lymphocytes. Th   ese conditions might promote persistent 
and non-physiological T-cell activation in autoimmunity 
[70]. But is there any evidence for the presence of similar 
structures in AAV?
At present, granulomas are regarded as some form of 
TLO in which immune responses are modiﬁ  ed [61,71]. 
For instance, Csernok and colleagues [72] revealed that 
PR3 is abundantly present in granulomas and renders 
DCs to powerful Th   1-cell activators. Moreover, Voswinkel 
and colleagues [73] demonstrated that aﬃ   nity maturation 
of B cells, as is commonly observed in lymphoid tissue, 
takes place in granulomas. It is suggested that the 
production of ANCA takes place locally within these 
granulomas. Granuloma formation in a classical manner 
is rarely present in the kidney, but some form of lymphoid 
neogenesis has been frequently observed in renal biopsies 
of patients with AAV [74-76]. Immature DCs and T cells 
form aggregates suggesting a cell-cell interaction. 
Strikingly, these DCs display costimulatory capability by 
expressing CD80 [75]. We hypothesize that, in the kidney, 
activation of Teﬀ   s and aggravation of the immune 
response take place. However, a local induction of Tregs 
and thus an attenuation of the inﬂ  ammatory  process 
seem to be possible, too [75,77]. Our own data indicate 
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(unpublished data). Th  e induction of Tregs is especially 
conﬁ   ned to places where abundant immature DCs 
bearing costimulatory properties are present [78]. 
Th   erefore, both local control of tissue inﬂ  ammation and 
activation of Teﬀ  s at the site of inﬂ  ammation are likely to 
occur in AAV (Figure 1).
Conclusion and implications for therapy
Circulating T cells in AAV show several abnormalities. 
T cells are disturbed in homeostasis and skewed toward 
memory and pro-inﬂ   ammatory T-cell types. Th  is 
knowledge might allow speciﬁ  c and targeted therapies in 
the future. At present, nearly all available treatment 
options for AAV are toxic and have severe side eﬀ  ects. 
Alternative treatment strategies such as cell-based 
therapy with ex vivo expansion of Tregs and subsequent 
infusion of these cells could potentially restore tolerance 
and T-cell homeostasis in AAV patients [79]. However, it 
has recently been reported that human Tregs can convert 
to pro-inﬂ   ammatory IL-17 - producing T cells in the 
presence of a speciﬁ   c cytokine environment (IL-1β, 
IL-21, IL-23) [80]. Th  us, administration of Tregs to 
patients might not restore tolerance but rather enhance 
autoimmunity under certain not-yet-known conditions. 
In light of these recent ﬁ  ndings on Treg plasticity, cell-
based approaches have to be considered with caution. In 
addition, control of T-cell activation might pose an 
attractive therapeutic option. In this regard, blockade of 
costimulatory pathways such as CD28/CD80 has 
successfully been used in rheumatoid arthritis and might 
be a therapeutic opportunity in AAV [81]. However, since 
an important T-cell population (CD28null T cells) involved 
in AAV pathogenesis is acting independently of the 
CD28/CD80 pathway, this novel strategy might not be 
applicable to all patient cohorts. As IL-2 is also involved 
in T-cell activation and is regarded as a ‘T-cell growth 
factor’, IL-2Rα (CD25)-blocking agents could be of use. 
Th  ese agents are already used in the ﬁ   eld of organ 
transplantation [82]. Th  ere is some evidence that anti-
CD25 antibody therapy is eﬀ   ective in autoimmune 
diseases such as multiple sclerosis and vasculitis [83,84]. 
Nevertheless, there are no reliable data available in AAV 
yet. Based upon the ﬁ   nding that CD25+ T cells are 
expanded in AAV and show an association with disease 
activity, there is at least a rationale to assume that anti-
CD25 agents might have a beneﬁ  cial  eﬀ  ect.  However, 
IL-2 has a role not only in maintaining but also in limiting 
immune responses. IL-2 shows homeostatic eﬀ  ects on 
Tregs and promotes activation-induced cell death; thus, 
adverse events facilitating autoimmunity cannot be 
excluded with certainty [85]. Next to the blockade of 
T-cell activation, it might be beneﬁ  cial to interfere with 
T-cell traﬃ     cking into tissues and thereby dampening 
inﬂ   ammation as well as granuloma formation. 
Natalizumab targets α4-integrin, which has a role in the 
adhesion of leukocytes to vascular endothelial cells, and 
thus prevents leukocyte migration [86]. It has been 
administered in patients suﬀ   ering from inﬂ  ammatory 
bowel disease and in cohorts with multiple sclerosis. In 
both cases, it was reported to be eﬀ  ective.  However, 
severe side eﬀ   ects such as multifocal leukoencephalo-
pathy have been reported in some cases [84]. Although 
the safety proﬁ  le of this drug needs further clariﬁ  cation, 
the basic mechanism of block  ing leukocyte adhesion 
might be a charming approach in AAV patients to 
dampen inﬂ  ammation and tissue destruction. Unraveling 
T cell-mediated pathology in AAV will provide further 
insights into disease mecha  nisms and will potentially 
result in promising new therapeutic options. It is hoped 
that further eﬀ  orts in this ﬁ  eld will allow a sustained 
restoration of self-tolerance in AAV patients.
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